Tarsus Pharmaceuticals Inc (NASDAQ: TARS) kicked off On Friday, up 5.13% from the previous trading day, before settling in for the closing price of $38.82. Over the past 52 weeks, TARS has traded in a range of $20.08-$57.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -66.60% over the past five years. While this was happening, its average annual earnings per share was recorded 60.02%. With a float of $38.25 million, this company’s outstanding shares have now reached $42.00 million.
Let’s look at the performance matrix of the company that is accounted for 323 employees. In terms of profitability, gross margin is 92.99%, operating margin of -46.72%, and the pretax margin is -44.91%.
Tarsus Pharmaceuticals Inc (TARS) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Tarsus Pharmaceuticals Inc is 8.95%, while institutional ownership is 101.39%. The most recent insider transaction that took place on Jun 17 ’25, was worth 550,035. In this transaction an insider of this company sold 13,608 shares at a rate of $40.42, taking the stock ownership to the 36,704 shares. Before that another transaction happened on Jun 17 ’25, when Company’s Officer proposed sale 13,608 for $40.42, making the entire transaction worth $550,088.
Tarsus Pharmaceuticals Inc (TARS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 60.02% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Take a look at Tarsus Pharmaceuticals Inc’s (TARS) current performance indicators. Last quarter, stock had a quick ratio of 5.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach 0.94 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) saw its 5-day average volume 0.71 million, a positive change from its year-to-date volume of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 19.29%.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 14.95%, which indicates a significant decrease from 33.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.67 in the past 14 days, which was lower than the 2.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.48, while its 200-day Moving Average is $46.51. Nevertheless, the first resistance level for the watch stands at $41.68 in the near term. At $42.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $44.13. If the price goes on to break the first support level at $39.23, it is likely to go to the next support level at $37.64. Assuming the price breaks the second support level, the third support level stands at $36.78.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
The company with the Market Capitalisation of 1.71 billion has total of 42,014K Shares Outstanding. Its annual sales at the moment are 182,950 K in contrast with the sum of -115,550 K annual income. Company’s last quarter sales were recorded 78,340 K and last quarter income was -25,120 K.
